Coppertone, BAY1183345

PreclinicalSmall molecule

Bayer

Coppertone, BAY1183345 is one of 37 small molecule programs targeting Adult. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AdultCompleted

AdultPreclinical

Completed

Competition

Competitive Landscape

127 competitors in Adult

#DrugCompanyPhaseTrials

Nydrazid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

1 2

Tebrazid

AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Phase 3

1 3

Mounjaro

Eli Lilly

Phase 2

1 4

Rifampicin

Boehringer Ingelheim

Phase 3

3 5

Myqorzo

CCytokinetics

Phase 3

1 6

Opzelura

DDizal Pharmaceuticals

Phase 2

1 7

NM8074

NNovelMed Therapeutics

Phase 2

2 8

EB-1020

Otsuka

Phase 3

1 9

Augtyro

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 1

1 10

Hytrin

AAbbott

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Adult1 trial

4 Week In-Use Study Evaluating How Well-Tolerated a Skin Care Product Is on Adults With Facial Redness

Completed· Bayer logo

Bayer·N/A·NCT03841032·35 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Coppertone, BAY1183345. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Coppertone, BAY1183345 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Coppertone, BAY1183345. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Bayer

Coppertone, BAY1183345

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Adult1 trial

References

Drug Info

Quick Facts

Related News